189 completed. 189 Phase 2, 28 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 189 | Completed 189 |
| Phase 1 | 28 | Completed 28 |
| Phase 3 | 4 | Completed 4 |
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer RC88 - Primary Peritoneal Cancer, Fallopian Tube Cancer | Phase 2 | Completed | RemeGen Co., Ltd. | 43 | 2024-01-19 | 2026-01-07 |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer KAND567, Carboplatin - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | Novakand Pharma AB | 18 | 2023-04-26 | 2025-06-08 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Mirvetuximab soravtansine - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Completed | AbbVie | 79 | 2021-10-19 | 2026-01-09 |
| Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy Second look laparoscopy reassessment surgery (SLLRS), HIPEC with Carboplatin, FACT-O Quality of Life Questionnaire - Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II | Phase 2 | Completed | Wake Forest University Health Sciences | 10 | 2021-05-20 | 2026-08-10 |
| Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Pembrolizumab, Computed Tomography - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | University of Washington | 22 | 2021-03-18 | 2026-06-29 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| Fertility Restoration Using Autologous Mesenchymal Stem Cells Autologous mesenchymal stem cells, standard treatment - Chronic Endometritis, Uterus; Scar | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 10 | 2020-10-01 | 2021-12-10 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer Pembrolizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | University College, London | 20 | 2019-05-16 | 2026-05-20 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Relacorilant, Nab-paclitaxel - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma | Phase 2 | Completed | Corcept Therapeutics | 178 | 2019-04-05 | 2025-10-07 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) tisotumab vedotin - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Seagen Inc. | 98 | 2019-03-20 | 2023-05-06 |
| Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Quality-of-Life Assessment, Questionnaire Administration - Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 50 | 2019-01-02 | 2026-08-21 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Takeda | 19 | 2018-12-28 | 2024-06-07 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer Niraparib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Takeda | 20 | 2018-12-26 | 2024-07-16 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Ganetespib, Niraparib, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 122 | 2018-11-30 | 2025-06-11 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC Atezolizumab, Bevacizumab, Cobimetinib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Peter MacCallum Cancer Centre, Australia | 30 | 2018-07-10 | 2026-10-28 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer Cediranib - Bowel Obstruction, Ovarian Cancer | Phase 2 | Completed | Prof Gordon Jayson | 30 | 2018-05-14 | 2026-06-15 |
| Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility Human Chorionic Gonadotropin (hCG), Gonadotropins, GNRH-A Triptorelin - Female Infertility, Female Infertility Due to Ovulatory Disorder | Phase 1 / Phase 2 | Completed | Lebanese University | 200 | 2018-02-01 | 2023-05-09 |
| DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer DCVAC/OvCa, Standard of Care Chemotherapy - Ovarian Cancer Recurrent | Phase 2 | Completed | SOTIO a.s. | 33 | 2017-11-23 | 2021-04-21 |
Showing 20 of 189. Sign in to see all of them.
Fallopian Tube Neoplasms (187) · Ovarian Neoplasms (156) · Carcinoma, Ovarian Epithelial (75) · Peritoneal Neoplasms (15) · Neoplasms (14) · Recurrence (13) · Brenner Tumor (9) · Breast Neoplasms (8) · Endometrial Neoplasms (8) · Uterine Cervical Neoplasms (7) · Carcinoma (6) · Sarcoma (4) · Neoplasm Metastasis (3) · Neoplasms, Glandular and Epithelial (3) · Ovarian Diseases (3)
Adnexal Diseases (189) · Female Urogenital Diseases (189) · Female Urogenital Diseases and Pregnancy Complications (189) · Genital Diseases (189) · Urogenital Diseases (189) · Genital Diseases, Female (188) · Genital Neoplasms, Female (186) · Gonadal Disorders (186) · Neoplasms by Site (186) · Urogenital Neoplasms (186) · Endocrine Gland Neoplasms (185) · Endocrine System Diseases (185) · Ovarian Diseases (183) · Neoplasms (174)
Carboplatin (42) · Paclitaxel (37) · Bevacizumab (23) · Taxes (12) · Gemcitabine (11) · Topotecan (10) · pembrolizumab (10) · Disulfides (9) · Immunoglobulin G (9) · liposomal doxorubicin (7) · Cisplatin (6) · Cyclophosphamide (6) · Docetaxel (6) · Erlotinib Hydrochloride (5) · niraparib (5)
National Cancer Institute (NCI) (31) · Gynecologic Oncology Group (11) · Memorial Sloan Kettering Cancer Center (8) · AGO Study Group (6) · M.D. Anderson Cancer Center (6) · Dana-Farber Cancer Institute (5) · Eli Lilly and Company (5) · Massachusetts General Hospital (4) · Roswell Park Cancer Institute (4) · University College, London (4) · GlaxoSmithKline (3) · Mayo Clinic (3) · Northwestern University (3) · SWOG Cancer Research Network (3) · University of Washington (3)
United States (144) · Canada (19) · United Kingdom (15) · Germany (12) · Spain (11) · Belgium (10) · France (7) · Italy (7) · Australia (6) · Japan (4) · Netherlands (4) · China (3) · Denmark (3) · Russia (3) · South Korea (3)
Ursula Matulonis, MD (4) · Amit Oza (3) · Emese Zsiros (3) · Paul Sabbatini, MD (3) · Robert Coleman (3) · Andreas du Bois, MD, PhD (2) · Bradley J Monk (2) · Bradley J. Monk, MD (2) · Daniela Matei, MD (2) · David R. Spriggs, MD (2) · Gerardo Colon-Otero (2) · Hal W. Hirte, MD, FRCP(C) (2) · Uwe Wagner, Prof.Dr. (2)
PMID 37185961, PMID 31685558, PMID 35170751, PMID 35397664, PMID 14645425, PMID 15661234, PMID 15699482, PMID 16014111, PMID 17161453, PMID 17330838, PMID 17910981, PMID 17918264, PMID 18538834, PMID 18829088, PMID 19138791, PMID 19181369, PMID 19238149, PMID 19264351, PMID 19464730, PMID 19922985, PMID 19922989, PMID 20357034, PMID 20837357, PMID 21144560, PMID 21168198, PMID 21412168, PMID 21733566, PMID 21752435, PMID 21815133, PMID 21935916, PMID 21992853, PMID 22377563, PMID 22487536, PMID 23474348, PMID 24709487, PMID 25016924, PMID 25070546, PMID 25254563, PMID 25318437, PMID 25462205, PMID 25488966, PMID 25589624, PMID 25895616, PMID 26026738, PMID 26588236, PMID 27217446, PMID 27908594, PMID 27998236, PMID 28453702, PMID 29186319
U10CA027469 (16), U10CA180868 (14), N01CM62203 (6), N01CM62201 (5), N01CM62209 (5), N01CM62204 (3), P30CA015083 (3), U10CA032102 (3), 2009 (2), 2017 (2), N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), N01CM62206 (2), N01CM62208 (2)